Cooper Companies Reports Increased Net Sales and Significant Profit Growth in Q3 Fiscal 2026

The Cooper Companies, Inc. reported a slight increase in net sales for the third quarter of fiscal 2026, reaching $1,066.2 million, compared to $1,060.3 million in the same period last year. For the nine months ending July 31, 2026, net sales totaled $3,171.8 million, up from $3,027.3 million in the prior year. The company’s gross profit for the quarter was $711.9 million, reflecting a gross margin of 67%, an increase from 65% in the previous year. Net income surged to $432.8 million, or $2.24 per diluted share, compared to $98.3 million, or $0.49 per diluted share, in the same quarter of 2025.

The financial performance indicates a significant recovery in profitability, with operating income for the quarter rising to $222.0 million from $175.7 million a year earlier. This increase was attributed to lower selling, general, and administrative expenses, which decreased to $401.3 million from $421.7 million. The company also reported a decrease in research and development expenses, which fell to $41.6 million from $44.6 million. The effective tax rate for the quarter was notably negative at (114.5)%, primarily due to the release of an uncertain tax position, which contributed to a discrete income tax benefit of $307.2 million.

In terms of strategic developments, Cooper Companies has been actively managing its capital structure, with a focus on share repurchases. The company repurchased 4.9 million shares for $339.1 million during the quarter, and as of July 31, 2026, had approximately $521.7 million remaining under its share repurchase authorization. The Board of Directors recently approved an increase in the share repurchase program to $3.0 billion, reflecting the company's commitment to returning value to shareholders.

Operationally, CooperVision, one of the company’s segments, reported net sales of $717.0 million for the quarter, slightly down from $718.4 million in the prior year. The decline was primarily due to lower sales of legacy hydrogel products, although the segment saw growth in its toric and multifocal lenses, driven by the success of the MyDay product line. CooperSurgical, the other segment, experienced a 2% increase in net sales to $349.2 million, supported by growth in both office and surgical offerings and fertility products.

Looking ahead, Cooper Companies remains optimistic about the long-term prospects for the contact lens and healthcare markets, despite facing significant risks including global economic uncertainties and regulatory challenges. The company plans to continue focusing on product innovation and market expansion, particularly in the silicone hydrogel segment, which is expected to drive future growth. The management's outlook emphasizes resilience and adaptability in navigating the evolving market landscape.